Scholarlink

Background <p>Heparinoid (Hirudoid®), a topical heparin-like agent, is labeled as contraindicated in bleeding disorders, yet its propensity for clinically relevant systemic anticoagulation remains uncertain.</p> Aim <p>To assess heparinoid’s anticoagulant potential in blood from healthy individuals and people with hemophilia (PwH).</p> Methods <p>In normal plasma exposed to heparinoid (≤ 6.5&#xa0;μg/mL) or heparin, and in plasma from PwH supplemented with FVIII or FIX (0–50&#xa0;IU/dL), we quantified activated partial thromboplastin time (APTT) and adjusted maximum coagulation velocity (Ad|min1|) by clot waveform analysis. In heparinoid-treated whole blood from healthy volunteers (≤ 9&#xa0;μg/mL), clotting time (CT) and clot formation time (CFT) were assessed by rotational thromboelastometry.</p> Results <p>In normal plasma, heparinoid dose-dependently prolonged APTT and reduced Ad|min1|; at the estimated <i>C</i><sub>max</sub> (2.5&#xa0;μg/mL), APTT increased ~ 1.2-fold and Ad|min1| approximated the effect of ~ 0.2&#xa0;IU/mL heparin. In FVIII- or FIX-supplemented plasma from PwH, Ad|min1| showed a mild, factor-level-dependent decrease (~ 85% of control). In whole blood, CT + CFT changed minimally at therapeutic concentrations. Heparin controls provided an internal benchmark for assay sensitivity.</p> Conclusion <p>At therapeutic levels, heparinoid exerts only mild anticoagulant effects in both normal and hemophilic matrices, supporting the view that topical use is unlikely to pose systemic bleeding risk in PwH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive anticoagulant effect of heparinoid in blood samples from patients with hemophilia

  • 期刊论文

  • 发表日期：

    2025年11月26日

查看全文
  • Tomoya Miyatake,
  • Masahiro Takeyama,
  • Kaoru Horiuchi,
  • Shoko Furukawa,
  • Kenichi Ogiwara,
  • Keiji Nogami

摘要

Background

Heparinoid (Hirudoid®), a topical heparin-like agent, is labeled as contraindicated in bleeding disorders, yet its propensity for clinically relevant systemic anticoagulation remains uncertain.

Aim

To assess heparinoid’s anticoagulant potential in blood from healthy individuals and people with hemophilia (PwH).

Methods

In normal plasma exposed to heparinoid (≤ 6.5 μg/mL) or heparin, and in plasma from PwH supplemented with FVIII or FIX (0–50 IU/dL), we quantified activated partial thromboplastin time (APTT) and adjusted maximum coagulation velocity (Ad|min1|) by clot waveform analysis. In heparinoid-treated whole blood from healthy volunteers (≤ 9 μg/mL), clotting time (CT) and clot formation time (CFT) were assessed by rotational thromboelastometry.

Results

In normal plasma, heparinoid dose-dependently prolonged APTT and reduced Ad|min1|; at the estimated Cmax (2.5 μg/mL), APTT increased ~ 1.2-fold and Ad|min1| approximated the effect of ~ 0.2 IU/mL heparin. In FVIII- or FIX-supplemented plasma from PwH, Ad|min1| showed a mild, factor-level-dependent decrease (~ 85% of control). In whole blood, CT + CFT changed minimally at therapeutic concentrations. Heparin controls provided an internal benchmark for assay sensitivity.

Conclusion

At therapeutic levels, heparinoid exerts only mild anticoagulant effects in both normal and hemophilic matrices, supporting the view that topical use is unlikely to pose systemic bleeding risk in PwH.